: OSU-03012, sorafenib, pazopanib and AR-13 alter chaperone -chaperone interactions assessed after immuno-precipitation. (A-C) GBM12 cells were treated with vehicle or with OSU-03012 (2 µM); sorafenib (2 µM); pazopanib (2 µM); for 10 min and then lysed. Immuno-precipitation of HSP90, GRP78, HSP27 and HSP70 was performed in the presence or absence of each drug individually (2 µM) for 3 h. Cells were washed with lysis buffer in the presence or absence of each drug individually (3 × 1 h, each). Immuno-precipitates were then boiled in SDS PAGE buffer containing glycerol and bromophenol blue. Proteins were separated on SDS PAGE (12% and 14% gels) and immunoblotting performed for the proteins as indicated. Figure S2 : Chaperone -protein interactions are regulated by OSU-03012. HeLa cells were pre-treated for 20 min with vehicle control (DMSO) or 5 µM OSU-03012 then lysed, and clarified lysates subjected to gel filtration on a Superdex column in the presence of the drug. Fractions of 1.0 ml were taken (15 fractions) and the protein precipitated from the fractions on ice using 10% (w/v) trichloro-acetic acid. Recovered protein was washed with cold 100% acetone. The protein pellets were boiled in SDS PAGE sample buffer containing bromophenol blue and subjected to SDS PAGE on 12% acrylamide gels, followed by western blotting to determine the elution profiles of HSP27.
Supplemantary Figure S3: In silico docking of OSU-03012 with the NH2-terminal ATP binding domain of HSP90.
(A) AR-12 docked into HSP90, first pose. (B) AR-12 docked into HSP90, second pose. (C) HSP90 in complex with AR12 (red) and apo-Hsp90 (green) after 30 ns of accelerated MD. The two poses are discussed in the results section -in both cases the amino group interacts in hydrogen bonding with S50 or D54 (or both). In the first pose, the CF3-group is engaged in hydrophobic interaction with Y139, and in the second one it is I110. Panel C. is free HSP90 and HSP90 in complex with AR-12 after 30 ns of accelerated MD. Figure S4A and is just from the docking. The data presented in Figure S4B has the ATP super-imposed. The phenanthrene group of OSU-03012 is in the nucleotide binding pocked (the arginine residues in this pocket may form cation-pi interactions), the -CF3 group seems to form hydrophobic interactions with one of the two tyrosines nearby, and the amino group in the side-chain interacts with the serines that would bind to the phosphate groups of ATP. Figure S6 : Kinase inhibitors disrupt chaperone -chaperone interactions in cells. GBM5 cells were treated with vehicle control or with: regorafenib (1 µM); sorafenib (1 µM); pazopanib (1 µM); AR-12 (OSU-03012) (1 µM); or AR-13 (1 µM) for 3 h. Cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to detect the expression of the indicated chaperones pair-wise. Images were merged in Adobe Photoshop to indicate areas of co-localization (red + green = yellow). Figure S7 : OSU-03012 and sorafenib regulate the phosphorylation and total protein expression levels of the autophagy regulatory proteins mTOR, ULK-1 and ATG13. (A) GBM5 and GBM12 cells were treated with vehicle, OSU-03012 (2.0 µM)/sorafenib (2.0 µM) and/or sildenafil (2 µM) for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to detect the expression levels of mTOR; ULK-1 and ATG13 as well as the phosphorylation of mTOR S2448; ULK-1 S757; ATG13 S318, presented at 10X magnification. (B and C) GBM12 cells from Panel A. were re-examined at 60X magnification to determine the localization of protein and localization of phosphorylated ULK-1 and ATG13 proteins. (D) GBM12 cells were transfected with empty vector (CMV), or plasmids to express GRP78 or HSP27. Twenty four h after transfection cells were treated with vehicle, OSU-03012 (2.0 µM) / sorafenib (2.0 µM) and/or sildenafil (2 µM) for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to detect the total expression levels of mTOR; eIF2α and ATG13 as well as the phosphorylation of mTOR S2448; eIF2α S51; ATG13 S318, presented at 10X magnification.
Supplemantary

Supplemantary Figure S9: Reduced thioredoxin (TRX) expression caused by OSU-03012 results in elevated levels of reactive oxygen species and increased amounts of tumor cell death. (A) GBM5 and GBM12 cells were treated with vehicle,
OSU-03012 (2.0 µM) / sorafenib (2.0 µM) and/or sildenafil (2 µM) for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to detect the expression levels of peroxiredoxin (PRX) and thioredoxin (TRX). (B) GBM6 cells were transfected with an empty vector plasmid, a plasmid to express TRX, or a plasmid to express a mutant inactive form of TRX. Twenty four h after transfection cells were treated with OSU-03012 (3 µM). At the indicated time points cells were incubated with DCFH to 10 min and then the levels of fluorescence, indicative of reactive species generation, were assessed in a Vector 3 plate reader (n = 6 +/− SEM). (C) GBM6 cells were transfected with an empty vector plasmid, a plasmid to express TRX, or a plasmid to express a mutant inactive form of TRX. Twenty four h after transfection cells were treated with OSU-03012 (3 µM). Twenty four h after drug exposure cell viability was determined by trypan blue exclusion assay (n = 3 +/−SEM). (D) Cells were transfected with an empty vector plasmid or plasmids to express GRP78 or HSP27, as indicated. Twenty four h after transfection cells were treated with vehicle, OSU-03012 (2.0 µM) / sorafenib (2.0 µM) and/or sildenafil (2 µM) for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to detect the expression levels of TRX.
